Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations.
about
Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptorsErk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2Essential function for ErbB3 in breast cancer proliferationDirect binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signalingHeart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptorsPhosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cellsMutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinaseNeuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathwayDifferential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytesNeuregulin facilitates nerve regeneration by speeding Schwann cell migration via ErbB2/3-dependent FAK pathwaySelective formation of ErbB-2/ErbB-3 heterodimers depends on the ErbB-3 affinity of epidermal growth factor-like ligands.Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor.The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer.Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.Take your partners, please--signal diversification by the erbB family of receptor tyrosine kinases.ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.Bivalence of EGF-like ligands drives the ErbB signaling networkHyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer.Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway.Sensory and motor neuron-derived factor is a transmembrane heregulin that is expressed on the plasma membrane with the active domain exposed to the extracellular environment.Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological responseLH-induced neuregulin 1 (NRG1) type III transcripts control granulosa cell differentiation and oocyte maturation.Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry.Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-AnalysisRole of HER2/HER3 co-receptor in breast carcinogenesis.ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4.A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder.Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapiesNeuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteinsCross-talk and modulation of signaling between somatostatin and growth factor receptors.The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1.The transmembrane heregulin precursor is functionally active.A Neu differentiation factor (NDF) domain essential for proliferation and alterations in morphology of colonic epithelial cells in vitro.Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes.
P2860
Q24532786-A3204C66-EEDA-4D05-A273-86BBF8C9644BQ24538180-C9ADDD5D-0FBF-4115-9777-CCAEDEDAED02Q24795054-142F11CB-F38D-41B5-AB0B-95ADC6BECE32Q28116711-F79DD983-456D-4BBA-BE53-4A9DBA56D895Q28215574-6FCE0C0D-5E5C-4761-AF07-72C4291290B1Q28269146-FDFC39E6-2E33-476B-BBFD-B4E717E83B67Q28278833-081220EC-7C5E-4566-8F9B-8CB88171ACF3Q28285114-9CEF4702-93B6-488F-B9C2-340BACA70D0BQ28360375-4BD766A4-ADB5-4A40-A434-C2066B3C6A37Q28484778-C04AFBDA-392D-4B8A-A2D2-C4C6D9EB7F2BQ30884331-E79A65B8-A4D0-467F-8D81-C35E8C2BA3FAQ30988881-889D3FC8-4391-4D95-9951-9F6925D6A076Q33538424-B14080FC-6340-403C-AB46-70E80718F3F2Q33576337-C40CA6AA-8F17-4463-AF4E-4DF8184041FBQ33700160-E2728801-4419-4FB9-BB29-EA6B4F0F0BB1Q33781099-5C9DA40F-520C-4281-B44C-ED50F37A1D10Q33801908-6FD68BE6-3968-401F-8772-E509748AEDE9Q33887274-AFB02F09-C68F-4EEF-9093-8AB199961D9FQ33887610-AF6F6714-9D97-4B20-83A9-15BB6840DB23Q33888963-33439616-9AC3-401E-AFA5-48838D413E27Q34062716-55624F8A-7F40-4FE0-BB0C-DFEF47EAFA89Q34478797-C1F1A52C-6EA1-40E6-B5CC-6F0900194565Q34600838-9AAE5054-5EA3-492B-B360-AD017875365AQ34942928-C5402212-BB00-4A2E-B0FA-71C86D76D2FCQ35121287-04EBF4DE-0126-454A-B284-7C6D84643AC2Q36238822-E8398B31-2107-43C5-9678-C2874C4643D0Q36429652-6A025A86-0A8C-45D6-A878-D88CF2701B88Q36490427-8AAB8D4D-C5EF-4086-B417-149528255127Q36610615-04FC042E-AA3B-4F9E-AFFC-DE46ADF88ABFQ36615866-29B34191-A6A5-45E6-832F-4C89E9CAB6A8Q36793441-4EA7D7AD-FE4B-4DBD-AB69-5836C9464560Q37241496-06F57A40-1476-49C1-A4EA-36740AC5E1D8Q37348865-C53AA6EC-23BF-4C90-AFD9-E130FD678400Q37355431-58E74F3F-5E5A-4BEF-8790-B863685DFF56Q37922648-A8B5C52C-288B-4559-A235-92083334B9C5Q39148511-22E8E513-82B1-4F3A-9FBA-7F08A236EA4CQ40000114-30817B9D-6B32-4CD6-B8FE-91C9A6F46562Q40787351-36585C39-2B9F-40C5-9A07-EE305C3946FFQ41014118-F887543C-099B-44D4-8345-505E2C2A0040Q41039377-62833D17-981F-4689-8A58-46A0F165DD73
P2860
Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations.
@en
type
label
Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations.
@en
prefLabel
Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations.
@en
P2093
P2860
P356
P1476
Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations
@en
P2093
P2860
P304
19029-19032
P356
10.1074/JBC.271.32.19029
P407
P577
1996-08-01T00:00:00Z